Neuralstem Receives NASDAQ Notice of Bid Price Deficiency GERMANTOWN, MD

Neuralstem Receives NASDAQ

Notice of Bid Price Deficiency

GERMANTOWN, MD, April 21, 2016 -- Neuralstem,

Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural

stem cell technology, announced that on April 20, 2016 it received a written notice from the NASDAQ Stock Market LLC that the Company

is not in compliance with NASDAQ Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been

below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing of the Company's

common stock, and its common stock will continue to trade on the NASDAQ Capital Market under the symbol "CUR" at this

In accordance with NASDAQ Listing Rule

5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 17, 2016, to regain compliance with the minimum

bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00

per share for at least ten consecutive business days during this 180 calendar day period.

In the event the Company does not regain

compliance by October 17, 2016, the Company may be eligible for an additional 180 calendar day grace period if it meets the initial

listing standards, with the exception of bid price, for the NASDAQ Capital Market, and provides written notice to NASDAQ of its

intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the

Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by NASDAQ,

NASDAQ will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled

to appeal the determination to a NASDAQ Listing Qualifications Panel and request a hearing.

Neuralstem's patented technology enables

the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential

therapies for many central nervous system diseases and conditions.

Neuralstem's ability to generate neural

stem cell lines from human hippocampus, which were used for systematic chemical screening for neurogenesis effect, has led to the

discovery and patenting of molecules that Neuralstem believes may stimulate the brain's capacity to generate new neurons, potentially

reversing pathophysiologies associated with certain central nervous system (CNS) conditions.

The Company has completed Phase 1a and

1b trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder

(MDD), and is expecting to initiate a Phase 2 efficacy study for MDD in 2016.

Neuralstem's first stem cell product candidate,

NSI-566, a spinal cord-derived neural stem cell line, is under development for treatment of amyotrophic lateral sclerosis (ALS).

Neuralstem has completed two clinical studies, in a total of thirty patients, which met primary safety endpoints. In addition to

ALS, NSI-566 is also in a Phase 1 study to treat paralysis due to chronic spinal cord injury, as well as in a Phase 1 study to

treat paralysis from ischemic stroke.

Cautionary Statement Regarding Forward

Looking Information:

This news release contains "forward-looking

statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect,"

"anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking

statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could

cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in

the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances,

need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may

differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors

that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports,

including the Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission

(SEC), and in other reports filed with the SEC.

Neuralstem - Investor Relations:

Planet Communications - Media Relations: